{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:32:11Z","timestamp":1793025131653,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thespinejournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Spine Journal"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.spinee.2025.07.030","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T19:23:06Z","timestamp":1752607386000},"page":"239-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The role of the iron-chelating agent deferoxamine in spinal cord injury: a systematic review and meta-analysis of preclinical studies"],"prefix":"10.1016","volume":"26","author":[{"given":"Mehrnaz","family":"Moradi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9430-7083","authenticated-orcid":false,"given":"Amirhossein","family":"Najibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Moshfeghinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6760-3623","authenticated-orcid":false,"given":"Afshin","family":"Heidarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrpour","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5722-6364","authenticated-orcid":false,"given":"Michael G.","family":"Fehlings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.spinee.2025.07.030_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.18","article-title":"Traumatic spinal cord injury","volume":"3","author":"Ahuja","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.spinee.2025.07.030_bib0008","series-title":"Translational neuroscience: fundamental approaches for neurological disorders","first-page":"389","article-title":"Pharmacological therapies for spinal cord injury","author":"Ahmed","year":"2025"},{"key":"10.1016\/j.spinee.2025.07.030_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.wneu.2021.02.116","article-title":"Updated review: the steroid controversy for management of spinal cord injury","volume":"150","author":"Canseco","year":"2021","journal-title":"World Neurosurg"},{"issue":"6","key":"10.1016\/j.spinee.2025.07.030_bib0010","doi-asserted-by":"crossref","first-page":"882","DOI":"10.4103\/1673-5374.184450","article-title":"Methylprednisolone for acute spinal cord injury: an increasingly philosophical debate","volume":"11","author":"Bowers","year":"2016","journal-title":"Neural Regen Res"},{"issue":"6","key":"10.1016\/j.spinee.2025.07.030_bib0011","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/10790268.2017.1329076","article-title":"Assessment and management of acute spinal cord injury: from point of injury to rehabilitation","volume":"40","author":"Hachem","year":"2017","journal-title":"J Spinal Cord Med"},{"issue":"2","key":"10.1016\/j.spinee.2025.07.030_bib0012","doi-asserted-by":"crossref","first-page":"281","DOI":"10.55782\/ane-2011-1848","article-title":"Secondary injury mechanisms in traumatic spinal cord injury: a nugget of this multiply cascade","volume":"71","author":"Oyinbo","year":"2011","journal-title":"Acta neurobiologiae experimentalis"},{"issue":"12","key":"10.1016\/j.spinee.2025.07.030_bib0013","first-page":"1117","article-title":"Programmed cell death comes in many flavors","volume":"29","author":"Cabon","year":"2013","journal-title":"Med Sci: M\/S"},{"issue":"4","key":"10.1016\/j.spinee.2025.07.030_bib0014","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/jcmm.13008","article-title":"Ferroptosis, a new form of cell death, and its relationships with tumourous diseases","volume":"21","author":"Yu","year":"2017","journal-title":"J Cell Mol Med"},{"issue":"3","key":"10.1016\/j.spinee.2025.07.030_bib0015","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12992","article-title":"Programmed cell death in spinal cord injury pathogenesis and therapy","volume":"54","author":"Shi","year":"2021","journal-title":"Cell Prolifer"},{"issue":"21","key":"10.1016\/j.spinee.2025.07.030_bib0007","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/BRS.0000000000004417","article-title":"Spinal cord injury: the global incidence, prevalence, and disability from the global burden of disease study 2019","volume":"47","author":"Ding","year":"2022","journal-title":"Spine"},{"issue":"1","key":"10.1016\/j.spinee.2025.07.030_bib0016","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","article-title":"Regulation of ferroptotic cancer cell death by GPX4","volume":"156","author":"Yang","year":"2014","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.spinee.2025.07.030_bib0017","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1182\/blood.V97.4.1115","article-title":"ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture","volume":"97","author":"Hershko","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.spinee.2025.07.030_bib0018","unstructured":"Velasquez J., Wray A.A., Deferoxamine. 2023 May 22. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. https:\/\/pubmed.ncbi.nlm.nih.gov\/32491586\/."},{"issue":"8","key":"10.1016\/j.spinee.2025.07.030_bib0019","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.4103\/1673-5374.274344","article-title":"Neuroprotective effect of deferoxamine on erastin-induced ferroptosis in primary cortical neurons","volume":"15","author":"Zhang","year":"2020","journal-title":"Neural Regener Res"},{"issue":"5","key":"10.1016\/j.spinee.2025.07.030_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127256","article-title":"Efficacy of deferoxamine in animal models of intracerebral hemorrhage: a systematic review and stratified meta-analysis","volume":"10","author":"Cui","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.spinee.2025.07.030_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2023.107634","article-title":"Deferoxamine in intracerebral hemorrhage: systematic review and meta-analysis","volume":"227","author":"Sun","year":"2023","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.spinee.2025.07.030_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116777","article-title":"Targeting ferroptosis in neuroimmune and neurodegenerative disorders for the development of novel therapeutics","volume":"176","author":"Li","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.spinee.2025.07.030_bib0023","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.brainres.2017.09.019","article-title":"Deferoxamine enhances alternative activation of microglia and inhibits amyloid beta deposits in APP\/PS1 mice","volume":"1677","author":"Zhang","year":"2017","journal-title":"Brain Res"},{"issue":"2","key":"10.1016\/j.spinee.2025.07.030_bib0024","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14607","article-title":"Efficacy of the iron-chelating agent, deferiprone, in patients with Parkinson's disease: a systematic review and meta-analysis","volume":"30","author":"Negida","year":"2024","journal-title":"CNS Neurosci Therap"},{"key":"10.1016\/j.spinee.2025.07.030_bib0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.expneurol.2013.03.017","article-title":"Chronic intranasal deferoxamine ameliorates motor defects and pathology in the \u03b1-synuclein rAAV Parkinson's model","volume":"247","author":"Febbraro","year":"2013","journal-title":"Experim Neurol"},{"key":"10.1016\/j.spinee.2025.07.030_bib0026","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.brainres.2014.05.048","article-title":"Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson\u05f3 s disease","volume":"1574","author":"Fine","year":"2014","journal-title":"Brain Res"},{"key":"10.1016\/j.spinee.2025.07.030_bib0027","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.expneurol.2016.03.016","article-title":"Deferoxamine-mediated up-regulation of HIF-1\u03b1 prevents dopaminergic neuronal death via the activation of MAPK family proteins in MPTP-treated mice","volume":"280","author":"Guo","year":"2016","journal-title":"Experim Neurol"},{"key":"10.1016\/j.spinee.2025.07.030_bib0028","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.freeradbiomed.2013.01.027","article-title":"Lipophilic adamantyl-or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease","volume":"60","author":"Liddell","year":"2013","journal-title":"Free Radical Biol Med"},{"issue":"7","key":"10.1016\/j.spinee.2025.07.030_bib0029","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1039\/C7MT00039A","article-title":"Analogues of desferrioxamine B designed to attenuate iron-mediated neurodegeneration: synthesis, characterisation and activity in the MPTP-mouse model of Parkinson\u2019s disease\u2020","volume":"9","author":"Gotsbacher","year":"2017","journal-title":"Metallomics"},{"issue":"26","key":"10.1016\/j.spinee.2025.07.030_bib0030","doi-asserted-by":"crossref","first-page":"E1649","DOI":"10.1097\/BRS.0000000000000055","article-title":"Comparison of deferoxamine and methylprednisolone: protective effect of pharmacological agents on lipid peroxidation in spinal cord injury in rats","volume":"38","author":"Dinc","year":"2013","journal-title":"Spine (Phila Pa 1976)"},{"issue":"6","key":"10.1016\/j.spinee.2025.07.030_bib0031","doi-asserted-by":"crossref","first-page":"959","DOI":"10.4103\/1673-5374.208591","article-title":"Mechanisms underlying the promotion of functional recovery by deferoxamine after spinal cord injury in rats","volume":"12","author":"Hao","year":"2017","journal-title":"Neural Regen Res"},{"issue":"8","key":"10.1016\/j.spinee.2025.07.030_bib0032","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.injury.2010.08.028","article-title":"Protective effect of deferoxamine on experimental spinal cord injury in rat","volume":"42","author":"Liu","year":"2011","journal-title":"Injury"},{"issue":"188","key":"10.1016\/j.spinee.2025.07.030_bib0033","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.24976\/Discov.Med.202436188.173","article-title":"Association of microbleeds on susceptibility-weighted imaging with ferroptosis and prognosis in rabbits with spinal cord injury","volume":"36","author":"Liu","year":"2024","journal-title":"Discov Med"},{"key":"10.1016\/j.spinee.2025.07.030_bib0034","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.wneu.2019.08.246","article-title":"Attenuation of white matter damage following deferoxamine treatment in rats after spinal cord injury","volume":"137","author":"Shi","year":"2020","journal-title":"World Neurosurg"},{"issue":"9","key":"10.1016\/j.spinee.2025.07.030_bib0035","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s12031-020-01564-1","article-title":"Deferoxamine ameliorates compressed spinal cord injury by promoting neovascularization in rats","volume":"70","author":"Tang","year":"2020","journal-title":"J Mol Neurosci"},{"issue":"3","key":"10.1016\/j.spinee.2025.07.030_bib0036","doi-asserted-by":"crossref","first-page":"e1344","DOI":"10.1002\/jsp2.1344","article-title":"Silibinin promotes healing in spinal cord injury through anti-ferroptotic mechanisms","volume":"7","author":"Vahabi","year":"2024","journal-title":"JOR Spine"},{"issue":"7","key":"10.1016\/j.spinee.2025.07.030_bib0037","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134371","article-title":"Pharmacological suppression of CNS scarring by deferoxamine reduces lesion volume and increases regeneration in an In vitro model for astroglial-fibrotic scarring and in rat spinal cord injury In vivo","volume":"10","author":"Vogelaar","year":"2015","journal-title":"PLoS One"},{"issue":"35","key":"10.1016\/j.spinee.2025.07.030_bib0038","first-page":"2751","article-title":"Deferoxamine improves neurological function in a rat model of experimental spinal cord injury","volume":"6","author":"Wang","year":"2011","journal-title":"Neural Regen Res"},{"issue":"3","key":"10.1016\/j.spinee.2025.07.030_bib0039","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4103\/1673-5374.245480","article-title":"Deferoxamine promotes recovery of traumatic spinal cord injury by inhibiting ferroptosis","volume":"14","author":"Yao","year":"2019","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.spinee.2025.07.030_bib0040","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.spinee.2025.07.030_bib0041","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/01.STR.0000125719.25853.20","article-title":"Pooling of animal experimental data reveals influence of study design and publication bias","volume":"35","author":"Macleod","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.spinee.2025.07.030_bib0042","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jneumeth.2013.09.010","article-title":"Meta-analysis of data from animal studies: a practical guide","volume":"221","author":"Vesterinen","year":"2014","journal-title":"J Neurosc Methods"},{"issue":"1","key":"10.1016\/j.spinee.2025.07.030_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.spinee.2025.07.030_bib0044","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jdent.2018.05.003","article-title":"Heterogeneity in Cochrane and non-Cochrane meta-analyses in orthodontics","volume":"74","author":"Koletsi","year":"2018","journal-title":"J Dent"},{"key":"10.1016\/j.spinee.2025.07.030_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1136143","article-title":"Ferroptosis is a new therapeutic target for spinal cord injury","volume":"17","author":"Bai","year":"2023","journal-title":"Front Neurosci"},{"issue":"8","key":"10.1016\/j.spinee.2025.07.030_bib0046","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/sc.2016.187","article-title":"Animal models of spinal cord injury: a systematic review","volume":"55","author":"Sharif-Alhoseini","year":"2017","journal-title":"Spinal Cord"},{"issue":"7","key":"10.1016\/j.spinee.2025.07.030_bib0047","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/brainsci11070846","article-title":"The current role of Dexmedetomidine as neuroprotective agent: an updated review","volume":"11","author":"Liaquat","year":"2021","journal-title":"Brain Sci"},{"issue":"6","key":"10.1016\/j.spinee.2025.07.030_bib0048","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2174\/1566524022666220525142954","article-title":"Dexmedetomidine attenuates spinal cord ischemia-reperfusion injury in rabbits by decreasing oxidation and apoptosis","volume":"23","author":"Liu","year":"2023","journal-title":"Curr Mol Med"},{"issue":"5","key":"10.1016\/j.spinee.2025.07.030_bib0049","first-page":"683","article-title":"Neurological recovery following traumatic spinal cord injury: a systematic review and meta-analysis","volume":"30","author":"Khorasanizadeh","year":"2019","journal-title":"J Neurosurg: Spine SPI"},{"issue":"8","key":"10.1016\/j.spinee.2025.07.030_bib0050","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1089\/neu.2009.1152","article-title":"Assessment of impairment in patients with acute traumatic spinal cord injury: a systematic review of the literature","volume":"28","author":"Furlan","year":"2011","journal-title":"J Neurotrauma"},{"issue":"5","key":"10.1016\/j.spinee.2025.07.030_bib0051","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s11999-016-5133-4","article-title":"Classifications In brief: american Spinal Injury Association (ASIA) impairment scale","volume":"475","author":"Roberts","year":"2017","journal-title":"Clinical Orthop Rel Res"},{"key":"10.1016\/j.spinee.2025.07.030_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2025.115169","article-title":"Outcome measures in rodent models for spinal cord injury and their human correlates","volume":"386","author":"Jones","year":"2025","journal-title":"Exp Neurol"},{"issue":"1","key":"10.1016\/j.spinee.2025.07.030_bib0053","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/1673-5374.243694","article-title":"Differences in neuroplasticity after spinal cord injury in varying animal models and humans","volume":"14","author":"Filipp","year":"2019","journal-title":"Neural Regen Res"},{"issue":"2","key":"10.1016\/j.spinee.2025.07.030_bib0054","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s13311-011-0034-4","article-title":"Plasticity after spinal cord injury: relevance to recovery and approaches to facilitate it","volume":"8","author":"Onifer","year":"2011","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.spinee.2025.07.030_bib0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0037-1963(01)90061-7","article-title":"Deferoxamine pharmacokinetics","volume":"38","author":"Porter","year":"2001","journal-title":"Semin Hematol"},{"issue":"20","key":"10.1016\/j.spinee.2025.07.030_bib0056","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJM199005173222001","article-title":"A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National acute spinal Cord Injury Study","volume":"322","author":"Bracken","year":"1990","journal-title":"N Engl J Med"},{"issue":"3 Suppl","key":"10.1016\/j.spinee.2025.07.030_bib0004","doi-asserted-by":"crossref","first-page":"84s","DOI":"10.1177\/2192568217703387","article-title":"A clinical practice Guideline for the management of acute spinal cord injury: introduction, rationale, and scope","volume":"7","author":"Fehlings","year":"2017","journal-title":"Global Spine J"},{"issue":"17\u201318","key":"10.1016\/j.spinee.2025.07.030_bib0057","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1089\/neu.2023.0163","article-title":"Safety and efficacy of riluzole in acute spinal cord injury study (RISCIS): a multi-center, randomized, placebo-controlled, double-blinded trial","volume":"40","author":"Fehlings","year":"2023","journal-title":"J Neurotrauma"},{"issue":"4","key":"10.1016\/j.spinee.2025.07.030_bib0058","doi-asserted-by":"crossref","DOI":"10.3390\/ph11040109","article-title":"New perspectives in iron chelation therapy for the treatment of neurodegenerative diseases","volume":"11","author":"Nu\u00f1ez","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"10.1016\/j.spinee.2025.07.030_bib0059","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s41393-022-00795-w","article-title":"Epidemiology of traumatic spinal cord injury: a large population-based study","volume":"60","author":"Barbiellini Amidei","year":"2022","journal-title":"Spinal Cord"},{"key":"10.1016\/j.spinee.2025.07.030_bib0060","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.expneurol.2015.04.008","article-title":"Large animal and primate models of spinal cord injury for the testing of novel therapies","volume":"269","author":"Kwon","year":"2015","journal-title":"Exp Neurol"},{"issue":"7","key":"10.1016\/j.spinee.2025.07.030_bib0061","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1161\/STROKEAHA.121.037298","article-title":"Effect of deferoxamine on trajectory of recovery after intracerebral hemorrhage: a post hoc analysis of the i-DEF trial","volume":"53","author":"Foster","year":"2022","journal-title":"Stroke"},{"issue":"8","key":"10.1016\/j.spinee.2025.07.030_bib0062","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3390\/antiox10081270","article-title":"Targeting pro-oxidant iron with deferoxamine as a treatment for ischemic stroke: safety and optimal dose selection in a randomized clinical trial","volume":"10","author":"Mill\u00e1n","year":"2021","journal-title":"Antioxidants"},{"issue":"22","key":"10.1016\/j.spinee.2025.07.030_bib0063","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1056\/NEJMoa2209254","article-title":"Trial of deferiprone in Parkinson\u2019s disease","volume":"387","author":"Devos","year":"2022","journal-title":"New England J Med"},{"issue":"11","key":"10.1016\/j.spinee.2025.07.030_fur1","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/sc.2017.56","article-title":"The impact of spinal cord injury on the quality of life of primary family caregivers: a literature review","volume":"55","author":"Lynch","year":"2017","journal-title":"Spinal Cord"},{"issue":"9304","key":"10.1016\/j.spinee.2025.07.030_fur2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(02)07603-1","article-title":"Spinal-cord injury","volume":"359","author":"McDonald","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.spinee.2025.07.030_fur3","doi-asserted-by":"crossref","unstructured":"Fehlings M.G., Moghaddamjou A., Evaniew N., Tetreault L.A., Alvi M.A., Skelly A.C., et al. The 2023 AO spine-Praxis guidelines in acute spinal cord injury: what have we learned? What are the critical knowledge gaps and barriers to implementation? Global Spine J 2024;14(3_suppl):223S\u2013230S.","DOI":"10.1177\/21925682231196825"},{"issue":"11","key":"10.1016\/j.spinee.2025.07.030_fur4","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S1474-4422(23)00287-9","article-title":"regional, and national burden of spinal cord injury, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study","volume":"22","author":"Safdarian","year":"2019","journal-title":"The Lancet Neurol"}],"container-title":["The Spine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1529943025003481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1529943025003481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:51:17Z","timestamp":1777618277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1529943025003481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1529943025003481"],"URL":"https:\/\/doi.org\/10.1016\/j.spinee.2025.07.030","relation":{},"ISSN":["1529-9430"],"issn-type":[{"value":"1529-9430","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of the iron-chelating agent deferoxamine in spinal cord injury: a systematic review and meta-analysis of preclinical studies","name":"articletitle","label":"Article Title"},{"value":"The Spine Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.spinee.2025.07.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}